Background: Severe heart failure (HF) patients often have renal dysfunction because of low cardiac output. Methods and Results: 39 patients underwent a centrifugal-type, continuous-flow left ventricular assist device (LVAD) (EVAHEART) implantation as a bridge to cardiac transplantation at our institute between 2005 and 2015. We investigated the changes in renal function over 2 years among 36 patients with supported by EVAHEART over 6 months. The median estimated glomerular filtration rate (eGFR) at implantation was 62 ± 32 mL/min/1.73 m2 and 47% of the patients showed eGFR < 60 mL/min/1.73 m2. The changes in renal function were shown in the Figure. Conclusions: EVAHEART, a centrifugal-type, continuous-flow LVAD improved patients' renal function early after implantation, however, gradually showed declining in most patients over 2 years.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Cardiac Failure
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect